Hulk Hogan, wrestling icon, dies at 71 in Florida home
CARMIEL, Israel - Protalix BioTherapeutics, Inc. (NYSE American:PLX), a profitable biopharmaceutical company with a strong balance sheet currently trading at $1.45, announced today the appointment of Gilad Mamlok as Senior Vice President and Chief Financial Officer, effective August 24, 2025. Mamlok will succeed Eyal Rubin, who will remain available to the company until October 2025 to ensure a smooth transition. According to InvestingPro data, the company maintains a healthy financial position with liquid assets exceeding short-term obligations.
Mamlok brings three decades of experience in healthcare and technology companies to Protalix. Most recently, he served as Chief Financial Officer at TytoCare Ltd., a private remote healthcare company. His previous experience includes serving as CFO at Sol-Gel Technologies Ltd., where he managed an initial public offering and various licensing transactions. He also worked at medical device companies including Given Imaging, which was acquired by Covidien in 2014.
The new CFO holds a BA in Economics, magna cum laude, and a Master’s degree in Business/Managerial Economics from Tel Aviv University.
"With his three decades of experience in healthcare and technology companies, Gilad will play a pivotal role in the execution of our growth strategy," said Dror Bashan, Protalix’s President and Chief Executive Officer, in a press release statement. The company, with a market capitalization of $115.43 million, has demonstrated resilience with its stock typically moving counter to market trends, as revealed by its negative beta of -0.23 according to InvestingPro analysis.
Protalix BioTherapeutics is a biopharmaceutical company that develops recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. The company’s first product, taliglucerase alfa for Gaucher disease, has been licensed to Pfizer for worldwide development and commercialization, except in Brazil. Its second product, Elfabrio, received approval from both the FDA and European Medicines Agency in May 2023.
The company has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio and maintains a development pipeline of other recombinant therapeutic proteins targeting established pharmaceutical markets.
In other recent news, Protalix Biotherapeutics Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $3.6 million, or an earnings per share (EPS) of -$0.05. This outcome fell short of analysts’ expectations, which had forecasted a positive EPS of $0.03. The company’s revenue also missed projections, coming in at $10.1 million, significantly below the expected $21.6 million. Despite this, Protalix noted a 170% increase in revenue from selling goods compared to the same period in 2024, largely due to increased sales to partners like Pfizer and Fearcruz. Additionally, Protalix is advancing its clinical pipeline, with plans to initiate a Phase II trial for its gout treatment, PRX-115, later this year. The company also anticipates potential regulatory milestones with its partner Chiesi, which could amount to $75 million. Analyst reactions were not explicitly detailed, but the financial shortfall indicates a need for careful monitoring of the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.